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Background: Interleukin (IL)-36 cytokines are recently reported member of the IL-1
cytokine family. However, there is little information regarding the association between
IL-36 cytokines and gut inflammation. In the present study, we investigated the biological
activity of IL-36α and IL-36γ using human colonic subepithelial myofibroblasts (SEMFs).
Methods: The mRNA expression and the protein expression of target molecules in
SEMFs were evaluated using real-time polymerase chain reaction and enzyme-linked
immunosorbent assay, respectively. The intracellular signaling of IL-36 cytokines was
analyzed using Western blot analysis and small interfering RNAs (siRNAs) specific for
MyD88 adaptor proteins (MyD88 and IRAK1) and NF-κB p65.
Results: IL-36α and IL-36γ significantly enhanced the secretion of IL-6 and CXC
chemokines (CXCL1, CXCL2, and CXCL8) by SEMFs. The combination of IL-36α/γ
and IL-17A or of IL-36α/γ and tumor necrosis factor-α showed a synergistic effect on
the induction of IL-6 and CXC chemokines. The mRNA expression of proinflammatory
mediators induced by IL-36α and/or IL-36γ was significantly suppressed by transfection
of siRNA for MyD88 or IRAK1. Both inhibitors of mitogen activated protein kinases and
siRNAs specific for NF-κBp65 significantly reduced the expression of IL-6 and CXC
chemokines induced by IL-36α and/or IL-36γ.
Conclusion: These results suggest that IL-36α and IL-36γ contribute to gut inflammation
through the induction of proinflammatory mediators.
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Introduction
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD),
is characterized by chronic inflammation in the gastrointestinal tract (1–3). A dysfunction of the
host immune response to dietary factors and/or the gut microbiota has been reported to play an
important role in the pathogenesis (4–9).
IL-36 is a novel IL-1 cytokine family member and consists of IL-36α, IL-36β, IL-36γ, IL-38, and
IL-36 receptor antagonist (IL-36Ra) (10–13). IL-36 cytokines were initially identified through the
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use of DNA database searches for homologs to IL-1 (14). IL-36
cytokines bind to the IL-36 receptor (IL-36R) and use the IL-1
receptor accessory protein (IL-1RAcp) as a co-receptor (14, 15),
leading to the activation of NF-κB and MAPK pathways (10, 14).
Recent studies showed that IL-36 cytokines play an important role
in the pathogenesis of psoriasis (16–20), rheumatoid arthritis (21–
23) or pulmonary disease (24, 25). However, there are few reports
regarding the function of IL-36 in gut inflammation.
Human colonic subepithelial myofibroblasts (SEMFs) are
located immediately subjacent to the basement membrane in nor-
mal intestinal mucosa, juxtaposed against the bottom of epithelial
cells (26, 27). We have previously reported that human colonic
SEMFs play an important role in chronic inflammation and
wound healing in the intestine and contribute to the pathogenesis
of IBD (26, 27).
In the present study, to explore the potential role of IL-36
cytokines in gut inflammation, we investigated the biological
functions and the signal transduction of IL-36α and IL-36γ in
human colonic SEMFs.
Materials and Methods
Reagents
Recombinant human IL-36α and TNF-α were purchased from
R&D Systems Inc. (Minneapolis, MN, USA). Human IL-36γ and
IL-17A were purchased from Pepro Tech Inc. (Rocky Hill, NJ,
USA). Inhibitors of MEK1 that is upstream of p42/44 ERK1/2
(PD98059 and U0126) and an inhibitor of the p38 MAPK
(SB203580) were purchased from Cell Signaling Technology
(Tokyo, Japan). The siRNAs specific for MyD88, IRAK1, and NF-
κBp65 and a control siRNA were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Human Colonic Subepithelial Myofibroblasts
Primary colonic SEMFs cultures were prepared from normal
colonic tissues according to the method reported by Mahida et al
(28). Normal colonic tissues were obtained from surgical spec-
imens (>5 cm from the tumor margin) of patients undergoing
a partial colectomy for carcinoma. The cells were cultured in
DMEM (Nacalai Tesque Inc., Kyoto, Japan) containing 10% fetal
bovine serum. All culturemedia were supplemented with 50U/ml
penicillin and 50μg/ml streptomycin. Over 98% of the cells were
immune-positive for α-SMA, a marker of myofibroblasts. The
studies were performed on passages two to six of myofibroblasts
isolated from four different resection specimens. All experiments
and all protocols were approved by the ethical committee of Shiga
University of Medical Science. Written informed consent was
obtained from all subjects in compliance with the Declaration of
Helsinki.
Real-Time PCR Analysis
The mRNA expression in the samples was assessed using
real-time polymerase chain reaction (PCR) analyses. The
real-time PCR was performed using the Light Cycler 480
system (Roche Applied Science, Tokyo, Japan) and the
reagent SYBR Premix Ex Taq II (TAKARA, Otsu, Japan).
The oligonucleotide primers used in this study were as follows:
IL-6 sense primer, GGTACATCCTCGACGGCATCT; anti-sense
primer, GTGCCTCTTTGCTGCTTTCAC (NCBI Gene ID:
000600); CXCL8 sense primer, AGGGTTGCCAGATGCAA
TAC; anti-sense primer, GCAAACCCATTCAATTCCTG (NCBI
Gene ID: 000584); CXCL1 sense primer, TGTTTGAGCAT
CGCTTAGGA; anti-sense primer, GATCTCATTGGCCATTT
GCT (NCBI Gene ID: 001511); CXCL2 sense primer, GGATT
GCGCCTAATGTGTTT; anti-sense primer, CACTGGCCATT
TTCTTGGAT (NCBI Gene ID: 002089); β-actin sense primer,
TGACCCAGATCATGTTTGAGACCT; and β-actin anti-sense
primer, CCACGTCACACTTCATGATGATGGAG. The data
were normalized versus β-actin mRNA.
Enzyme-Linked Immunosorbent Assay
The concentrations of CXCL1, CXCL8, and IL-6 in the culture
medium were quantified using the human Quantikine ELISA
Kit (R&D Systems). CXCL2 was quantified using the Human
Omnikine ELISA Kit (Assay Biotech). All procedures were per-
formed according to the manufacturer’s protocol.
Western Blot Analysis
Human colonic SEMFswere exposed to IL-36α (100 ng/ml) or IL-
36γ (100 ng/ml) for pre-determined periods. The stimulated cells
were lysed in a protein extraction buffer (20mM Tris-HCl, 2mM
EDTA, 2mM EGTA, 150mM NaCl, 400mM sodium fluoride,
4mM sodium orthovanadate, 1% NP-40 Non-idet, containing
complete mini). Western blots were then performed accord-
ing to a method previously described (29). Antibodies against
phosphorylated and total MAPKs, IκBα and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), were purchased from Cell
Signaling Technology (Tokyo, Japan). The signal was detected
using the enhanced chemiluminescence western blotting system
(GE Healthcare, Little Chalfont, UK).
Small Interference RNA Experiments
Human colonic SEMFs were transfected with siRNA using Lipo-
fectamine RNAiMAX (Invitrogen) according to the manufac-
turer’s instructions. Briefly, cells were cultured in complete
medium in the presence of a mixture of an RNAi duplex and
Lipofectamine RNAiMAX for 24 h, and were then stimulated with
or without IL-36α or IL-36γ for 12 h.
Statistical Analysis
The statistical significance of the differences between groups
was determined using Student’s t-test. Data are expressed as
means SD (n= 4). Differences resulting in P-values<0.05 were
considered to be statistically significant.
Results
To investigate the function of IL-36 cytokines in human colonic
SEMFs, the cells were stimulated with IL-36α (100 ng/ml) or
IL-36γ (100 ng/ml) for 24 h, and themRNA expression of IL-6 and
CXC chemokines (CXCL1, CXCL2, and CXCL8) was evaluated
using real-time PCR. The secretion of IL-6 and CXC chemokine
proteins was also determined using ELISA. As it has been reported
that IL-36α, IL-36β, and IL-36γ can be activated by the removal of
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FIGURE 1 | IL-36α and IL-36γ induce IL-6 and CXC chemokine mRNA expression in human colonic SEMFs. (A) SEMFs were stimulated with IL-36α
(100 ng/ml) or IL-36γ (100 ng/ml) for 24 h. The mRNA expression for IL-6 and CXC chemokines (CXCL1, CXCL2, and CXCL8) was evaluated using real-time PCR.
The mRNA expression for IL-6 and chemokine was converted to a value relative to β-actin mRNA expression and presented as fold-increase relative to the results for
medium alone (no stimulation). Data are expressed as meansSD of four independent experiments. *P<0.05, **P<0.01; significant differences from the values for
medium alone. (B) SEMFs were incubated with IL-36α (100 ng/ml) or IL-36γ (100 ng/ml) for 24 h. The protein levels of IL-6 and CXC chemokines (CXCL1, CXCL2,
and CXCL8) in the culture medium were determined using ELISA. Data are expressed as meansSD of four independent experiments. *P<0.05, **P<0.01;
significant differences from the values for medium alone.
N-terminal residues, we used spliced recombinant IL-36 cytokines
(30). As shown in Figures 1A,B, both IL-36α and IL-36γ induced
a significant increase in themRNAand protein expression of these
proinflammatory mediators compared to the medium control.
These results indicate that IL-36α and IL-36γ are strong inducers
of proinflammatory mediators in human colonic SEMFs.
We investigated the induction of proinflammatory mediators
by IL-36α and IL-36γ in further detail. Human colonic SEMFs
were incubated for 24 h with increasing concentrations of IL-36α
or IL-36γ, and the secretion of CXC chemokines was measured
using ELISA. IL-36α or IL-36γ dose-dependently induced the
secretion of CXC chemokines (Figure 2A). We next evaluated
the protein expression of IL-6 and CXC chemokines. Human
colonic SEMFs were incubated with IL-36α (100 ng/ml) or IL-36γ
(100 ng/ml) for pre-determined times and the secretion of IL-6
and CXC chemokines was measured using ELISA. As shown in
Figure 2B, IL-36α and IL-36γ induced the secretion of proin-
flammatory mediators in a time-dependent manner (effects of
IL-36α and IL-36γ at the mRNA levels were shown in Figure S1
in Supplementary Material).
The combined effect of IL-36 and IL-17A or IL-36 and TNFα
on the mRNA production of inflammatory mediators was evalu-
ated using real-time PCR. As shown in Figure 3A, the combina-
tion of IL-36α and IL-17A or IL-36α and TNFα synergistically
enhanced the mRNA expression of IL-6 and CXC chemokines.
Similarly, simultaneous stimulation with IL-36γ and IL-17A or IL-
36γ and TNFα synergistically upregulated the mRNA expression
of IL-6 and CXC chemokines (Figure 3B).
We next investigated whether MyD88 adaptor proteins were
involved in the signal transduction of IL-36α or IL-36γ. For this
purpose, we employed siRNA transfection system to silence the
gene expression ofMyD88 adaptor proteins. As shown inFigure 4,
siRNA specific for MyD88 or IRAK1, but not control siRNA,
significantly suppressed the mRNA expression of IL-6 and CXC
chemokines (CXCL1, CXCL2, and CXCL8) in response to IL-36α
or IL-36γ [efficacy of siRNAs specific for MyD88, IRAK1, and
NF-κB65 was confirmed by real-time PCR (Figure S2 in Supple-
mentaryMaterial)]. These findings indicated thatMyD88 adaptor
proteins are essential for the intracellular signaling of both IL-36α
and IL-36γ for the induction of proinflammatory mediators.
It has previously been reported that IL-36 cytokines activate
MAPKs andNF-κB in Jurkat cells (14). To assess whether the acti-
vations of MAPKs are involved in the induction of IL-6 and CXC
chemokines (CXCL1, CXCL2, and CXCL8) by IL-36α or IL-36γ,
we evaluated the phosphorylation of MAPKs in IL-36-stimulated
human colonic SEMFs by Western blot analysis. As shown in
Figure 5A, both IL-36α and IL-36γ rapidly induced the phos-
phorylation of p42/44 MAPK, p38 MAPK, and JNK within 5min
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FIGURE 2 | IL-36α and IL-36γ dose- and time-dependently induce IL-6 and CXC chemokines in human colonic SEMFs. (A) Dose-dependent effects of
IL-36α or IL-36γ on IL-6 and CXC chemokines. SEMFs were stimulated for 24 h with increasing concentrations of IL-36α or IL-36γ, and the concentration of IL-6
and CXC chemokines (CXCL1, CXCL2, and CXCL8) secreted into the culture medium was determined using ELISA. Data are expressed as meansSD of four
independent experiments. *P<0.05, **P<0.01; significant differences from the values for medium (0 ng/ml) alone. (B) The kinetics of IL-6 and CXC chemokine
induction by IL-36α and IL-36γ. SEMFs were stimulated with 100 ng/ml of IL-36α or 100 ng/ml of IL-36γ for pre-determined times, and the protein levels of IL-6 and
CXC chemokines in the culture medium were measured using ELISA. Data are expressed as meansSD of four independent experiments. *P<0.05, **P<0.01;
significant differences from the values at 0 h.
after stimulation. Next, we examined the involvement of MAPKs
in the induction of IL-6 and CXC chemokines (CXCL1, CXCL2,
and CXCL8) by IL-36α or IL-36γ using specific inhibitors of p38
MAPK (SB203580) and of MEK1 (PD98059 and U0126) that is
directly upstream of p42/44MAPK. As shown in Figure 5B, inhi-
bition of p38 MAPK or of p42/44MAPK significantly reduced the
mRNA expression of IL-6 or CXC chemokines induced by IL-36α
or IL-36γ. These results indicated that the activation of MAPKs is
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FIGURE 3 | Effects of combination of IL-36α/γ plus IL-17A or that of IL-36α/γ plus TNF-α on the induction of IL-6 and CXC chemokines. SEMFs were
stimulated with combination of IL-36α/γ plus IL-17A or that of IL-36α/γ plus TNF-α for 24 h [(A) IL-36α plus IL-17A or IL-36α plus TNF-α, (B) IL-36γ plus IL-17A or
IL-36γ plus TNF-α]. The mRNA expression of IL-6 and CXC chemokines (CXCL1, CXCL2, and CXCL8) was then determined using real-time PCR. The mRNA
expression for IL-6 and chemokine was converted to a value relative to β-actin mRNA expression and presented as fold-increase relative to the results for medium
alone (no stimulation). Data are expressed as meansSD of four independent experiments. *P<0.05, **P<0.01; significant differences from the values for IL-17A
or TNF-α stimulation.
involved in the induction of proinflammatory mediators by both
IL-36α and IL-36γ in human colonic SEMFs.
The transcription factorNF-κBplays critical roles in themRNA
expression of inflammatory mediators. To investigate whether
IL-36α or IL-36γ induce the activation ofNF-κB, we evaluated the
effects of both IL-36α and IL-36γ on IκBα phosphorylation and
total IκBα degradation in human colonic SEMFs using western
blot analysis. As shown in Figure 6A, both IL-36α and IL-36γ
induced the phosphorylation and degradation of IκB. We also
examined the involvement of NF-κB activation in the induction
of IL-6 and CXC chemokines (CXCL1, CXCL2, and CXCL8) by
IL-36α or IL-36γ using a siRNA specific for NF-κBp65. Block-
ade of the expression of NF-κBp65 significantly suppressed the
induction of IL-6 and CXC chemokines (CXCL1, CXCL2, and
CXCL8) by IL-36α or IL-36γ (Figure 6B) [we confirmed that the
gene expression of NF-κBp65 was suppressed by the transfection
of siRNA specific for NF-κBp65 using real-time PCR (Figure S2
in SupplementaryMaterial)]. These results indicated that the acti-
vation of NF-κB is involved in the induction of proinflammatory
mediators by both IL-36α and IL-36γ.
Discussion
In the present study, we investigated the biological activity and the
intracellular signal transduction of IL-36α and IL-36γ in human
colonic SEMFs.We demonstrated that both IL-36α and IL-36γ are
strong inducers of proinflammatory mediators, such as IL-6 and
CXC chemokines (CXCL1, CXCL2, andCXCL8), and thatMyD88
adaptor proteins were essential for the signal transduction of both
IL-36α and IL-36γ. Furthermore, both IL-36α and IL-36γ induce
proinflammatorymediators through the activation ofMAPKs and
NF-κB.
It has been reported that IL-36 cytokines play an important
role in some human disorders, such as of psoriasis (16–18),
rheumatoid arthritis (21–23), or pulmonary disease (24, 25).
However, there is little information regarding the function of
IL-36 in inflammatory response in the intestine. We, there-
fore, investigated the biological activities of IL-36 using human
colonic SEMFs. We found that both IL-36α and IL-36γ strongly
induce the production of IL-6 and CXC chemokines (CXC1,
CXCL2, and CXCL8) in human colonic SEMFs. IL-6 has been
reported to be an important factor in the acute phase response
in various tissues via its broad proinflammatory actions (31),
and chemokines direct the recruitment and migration of cir-
culating leukocytes to inflammatory sites and determine the
composition of leukocytes in inflammation (32–34). Thus, our
results indicate that both IL-36α and IL-36γ contribute to
the gut inflammation through the induction of cytokine and
chemokine production from colonic SEMFs. Role of other mem-
ber of IL-36 cytokine family, such as IL-36β, IL-38, and IL-36Ra
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FIGURE 4 | Role of MyD88 adaptor proteins (MyD88 and IRAK1) in IL-36 signaling in human colonic SEMFs. SEMFs were transfected with siRNA specific
for the MyD88 adaptor proteins (MyD88 and IRAK1) or with control siRNA. The cells were incubated for 24 h with or without 100 ng/ml of IL-36α (upper panels) or
IL-36γ (lower panels). The mRNA expression of IL-6 and CXC chemokines (CXCL1, CXCL2, and CXCL8) was then evaluated using real-time PCR. The mRNA
expression for IL-6 and chemokine was converted to a value relative to β-actin mRNA expression and presented as fold-increase relative to the results for medium
alone (no stimulation). Data are expressed as meansSD of four independent experiments. *P<0.05, **P<0.01; significant differences from the values for IL-36α
or IL-36γ stimulation.
(13), in the gut inflammation should be investigated in the
future.
Various kinds of inflammatory mediators are involved in
intestinal inflammation, such as IBD (33). For example, we
have previously found that IL-17 expression is enhanced in the
inflamedmucosa of IBD patients (35). Pathological role of TNF-α
has been made clear by potent therapeutic effects of anti-TNF-α
drugs (36, 37). So, we investigated the interaction between
IL-36α/γ and IL-17A or between IL-36α/γ plus TNFα. We found
that simultaneous stimulation of SEMFs with combination of
IL-36α plus IL-17A or that of IL-36α plus TNFα synergistically
upregulated the induction of inflammatory mediators. Similar
results were detected by combination of IL-36γ plus IL-17A
or that of IL-36γ plus TNFα. These data suggest that both
IL-36α and IL-36γ may further enhance intestinal inflammation
through synergism with IL-17A or TNFα via induction of
proinflammatory mediators.
Receptors for IL-36 cytokines consist of IL-36R and the IL-1R
accessory protein (IL-1RAcP). Following binding to the IL-36R,
the IL-36/IL-36R complex recruits IL-1RAcP, leading to the acti-
vation of MAPK/NF-κB pathways (38). IL-36-mediated dimer-
ization of IL-1RAcp with IL-36R drives productive signaling
through engagement of cytoplasmic Toll/IL-1 receptor domains
(13). However, the intracellular signaling pathways of IL-36
cytokines have not fully been identified in any cell type. In this
study, we found that the activation of both MAPKs and NFκB is
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FIGURE 5 | Activation of MAPKs by IL-36α or IL-36γ in human colonic SEMFs. (A) SEMFs were stimulated with or without IL-36α (100 ng/ml) or IL-36γ
(100 ng/ml) for the indicated pre-determined times. Expression of phosphorylated (p-) and total MAPKs were sequentially evaluated by Western blotting. The data are
representative of two independent experiments. (B) SEMFs were pretreated with 20 μM of a p38 MAPK inhibitor (SB203580) or an MEK1/2 inhibitor (U0126 or
PD98059) for 1 h, and were then incubated with or without 100 ng/ml of IL-36α (top panels) or IL-36γ (bottom panels) for 24 h. The mRNA expression of IL-6 and
chemokines was then analyzed. The mRNA expression for IL-6 and chemokines was converted to a value relative to β-actin mRNA expression and presented as
fold-increase relative to the results for medium alone (no stimulation). Data are expressed as meansSD of four independent experiments. *P<0.05, **P<0.01;
significant differences from the values for IL-36α or IL-36γ stimulation.
essential for the signal transduction of IL-36α or IL-36γ in SEMFs.
Furthermore, we found that MyD88 adaptor proteins are critical
for IL-36α- and/or IL-36γ-mediated induction of proinflamma-
tory mediators.
In conclusion, we showed that both IL-36α and IL-36γ have
a potential role as a strong inducer of the production of proin-
flammatorymediators by human colonic SEMFs. These responses
were mediated by MyD88 signaling pathway followed by the
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FIGURE 6 | The activation of IκBα by IL-36α or IL-36γ in human colonic SEMFs. (A) SEMFs were stimulated with 100 ng/ml of IL-36α or IL-36γ for the
indicated pre-determined times. Expression of phosphorylated (p-) and total IκBα was sequentially evaluated by Western blotting. The data are representative of
three independent experiments. (B) SEMFs were transfected with NF-κBp65 siRNA and cultured for 2 days. The cells were then stimulated with or without 100 ng/ml
of IL-36α (top panels) or IL-36γ (bottom panels) for 24 h. The mRNA expression of IL-6 and the indicated chemokines was then evaluated using real-time PCR. The
mRNA expression for IL-6 and chemokine was converted to a value relative to β-actin mRNA expression and presented as fold-increase relative to the results for
medium alone (no stimulation). Data are expressed as meansSD of four independent experiments. *P<0.05, **P<0.01; significant differences from the values for
IL-36α or IL-36γ stimulation.
activation of MAPKs and NFκB. IL-36 may play an important
role in the inflammatory response in the colon and may be a new
therapeutic target of IBD.
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